Evidence map›Paper›PMID 38609845›Full record

ArticleBMC infectious diseases2024

Beyond prediction: unveiling the prognostic power of μ-opioid and cannabinoid receptors, alongside immune mediators, in assessing the severity of SARS-CoV-2 infection.

Masoumeh Tavakoli-Yaraki, Aida Abbasi, Fatemeh Nejat Pishkenari, Saeed Baranipour, Alireza Jahangirifard, Seyed Bashir Mirtajani, Zahra Noorani Mejareh, Mohammad Amin Vaezi, Jila Yavarian, Bahare Abdollahi and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Masoumeh Tavakoli-YarakiDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Aida AbbasiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, P.O. Box: 1417613151, Iran.
Fatemeh Nejat PishkenariDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Saeed BaranipourDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Alireza JahangirifardLung Transplant Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seyed Bashir MirtajaniLung Transplant Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra Noorani MejarehStudent Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mohammad Amin VaeziDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Jila YavarianDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, P.O. Box: 1417613151, Iran.
Bahare AbdollahiStudent Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Talat Mokhtari-AzadDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, P.O. Box: 1417613151, Iran.
Vahid SalimiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, P.O. Box: 1417613151, Iran. vsalimi@tums.ac.ir.ORCID http://orcid.org/0000-0002-8541-7846
Iran University of Medical Sciences · IRTehran University of Medical Sciences · IRMasih Daneshvari Hospital · IR

Funding

Iran University of Medical Sciences 99-1-4-17629
6 · The paper itself

Abstract

backgroundThis study aims to explore the potential of utilizing the expression levels of cannabinoid receptor 2 (CB2), μ-opioid receptor (MOR), MCP-1, IL-17, IFN-γ, and osteopontin as predictors for the severity of SARS-CoV-2 infection. The overarching goal is to delineate the pathogenic mechanisms associated with SARS-CoV-2.

methodsUsing quantitative Real-time PCR, we analyzed the gene expression levels of CB2 and MOR in nasopharynx specimens obtained from patients diagnosed with SARS-CoV-2 infection, with 46 individuals classified as having severe symptoms and 46 as non-severe. Additionally, we measured the circulating levels of MCP-1, IL-17, IFN-γ, and osteopontin using an ELISA assay. We examined the predictive capabilities of these variables and explored their correlations across all patient groups.

resultsOur results demonstrated a significant increase in MOR gene expression in the epithelium of patients with severe infection. The expression of CB2 receptor was also elevated in both male and female patients with severe symptoms. Furthermore, we observed concurrent rises in MCP-1, IL-17, IFN-γ, and osteopontin levels in patients, which were linked to disease severity. CB2, MOR, MCP-1, IL-17, IFN-γ, and osteopontin showed strong predictive abilities in distinguishing between patients with varying degrees of SARS-CoV-2 severity. Moreover, we identified a significant correlation between CB2 expression and the levels of MOR, MCP-1, osteopontin, and IFN-γ.

conclusionsThese results underline the interconnected nature of molecular mediators in a sequential manner, suggesting that their overexpression may play a role in the development of SARS-CoV-2 infections.

Indexed as

COVID-19Analgesics, OpioidFemaleHumansImmunologic FactorsInterleukin-17MaleOsteopontinPrognosisReceptors, CannabinoidSARS-CoV-2Analgesics, OpioidImmunologic FactorsInterleukin-17OsteopontinReceptors, CannabinoidCannabinoid receptorIFN-γIL-17MCP-1Opioid receptorOsteopontinPredictorSARS-CoV-2

Identifiers

PMID38609845
PMCPMC11015610
OpenAlexW4394747429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.